ProMetic strikes Brazilian licensing deal

Guest Contributor
March 26, 2007

Montreal's ProMetic Life Sciences Inc has entered into a technology transfer and licensing agreement with Brazil's Tecpar for the manufacture of a complex biopharmaceutical product for the South American market. The agreement combines a proprietary manufacturing process licensed from the National Research Council's Biotechnology Research Institute and ProMetic's bioseparation process using Mimetic Legand technology. Prometic will receive $9 million in licence, milestone and development payments, while state-owned Tecpar will spend $10 million to modify its existing facility. The project is expected to lead to a centre of excellence where other drugs can be produced. It also represents a key advance in ProMetic's global strategy for licensing enabling technologies....

Other News

Events For Leaders in
Science, Tech, Innovation, and Policy

Discuss and learn from those in the know at our virtual and in-person events.

See Upcoming Events

You have 1 free article remaining.
Don't miss out - start your free trial today.

Start your FREE trial    Already a member? Log in


By using this website, you agree to our use of cookies. We use cookies to provide you with a great experience and to help our website run effectively in accordance with our Privacy Policy and Terms of Service.